Abstract:Chagas disease (CD), a neglected tropical disease, is caused by infection by the protozoan Trypanosoma cruzi . One-third of CD patients develop cardiac disease (CARD), an inflammatory and fibrotic process that may progress to heart failure associated with reduced left ventricular ejection fraction (LVEF). The determinants of CD progression are still uncertain. In non-infectious conditions, the angiotensin-converting enzyme (ACE) functional insertion (I)/deletion (D) and type 1 angiotensin II receptor (AT 1 R) +1166A>C gene polymorphisms have been linked to clinical outcomes. In a Brazilian cohort of 402 patients with positive serology for CD, in a case-control study we used PCR for genotyping the ACE rs4646994 I/D and AGTR1 rs5182C>T, rs275653 -119C>T, rs2131127A>G and rs5186 +1166A>C polymorphisms to evaluate association with CARD and progression to heart failure. Patients were classified as non-CARD (stage A; 109), and mild (stage B1; 161) or severe (stage C; 132) CARD. The groups were compared using unconditional logistic regression analysis and adjusted for non-genetic covariates (age, gender, and trypanocidal treatment). ACE II genotype appeared less frequent in C patients (15% in C vs 20% in B1 and 27% in A). After covariate adjustments, the ACE D allele showed a borderline association with susceptibility to severe CARD (C vs A: OR = 1.9; P = 0.08). AGTR1 +1166AC genotype showed a borderline association with protection against the progression and severity of CARD (C vs A: OR = 0.6; P = 0.09; C vs B1: OR = 0.6; P = 0.07; C vs A + B1: OR = 0.6; P = 0.05). However, adjustments for multiple comparisons showed no association of ACE I/D and AGTR1 polymorphisms with susceptibility and severity of CARD. The rs275653/rs2131127/rs5186/rs5182 T/A/C/T haplotype was protective against progression to the severe form of CARD (C vs B1: OR = 0.3; P = 0.03). Moreover, patients with ACE II and AGTR1 rs5186 +1166AC genotypes presented higher LVEF%. In C patients, TNF serum levels were higher in ACE D carriers than in II genotype. Although limited in number, a cross-sectional observation suggests that C-stage patients treated with benznidazole years prior to administration of ACE inhibitors/AT 1 R antagonists show reduced TNF serum levels and improved LVEF%. Therefore, variants of ACE and AGTR1 genes may influence the outcome of Chagas' heart disease and should be explored in precision medicine. Further, pharmacotherapies may improve immunological abnormality and clinical outcome in CD patients. Altogether, these data support prospective studies of this cohort and replication in other cohorts. It is estimated that 6–7 million individuals worldwide are infected with Trypanosoma cruzi , the etiologic agent of Chagas disease (CD), a neglected illness that impacts public health. Chronic cardiopathy is the most severe manifestation of CD, an inflammatory and fibrotic process that can progress to heart failure with reduced left ventricular ejection fraction (LVEF). Host genetics may be a determining factor in the progression of CD. In a group of chronic CD patients, we evaluated genetic polymorphisms of members of the renin-angiotensin system ( ACE I/D; AGTR1 variants), essential in regulating blood pressure and cardiovascular events. ACE D allele carriers and AGTR1 rs5186 +1166AA genotype present worse LVEF. Thus, variants of ACE and AT 1 R genes may be involved in the outcome of Chagas' heart disease. Although studying a low number of patients with severe cardiopathy, our data suggest that etiological treatment years before therapy with cardioprotectors (ACE inhibitors/AT 1 R blockers) reduced serum levels of TNF, an inflammatory cytokine important in cardiac pathology, and improved LVEF. This paves the way for ACE and AGTR1 genotyping, and adoption of therapeutic regimens may be explored as strategies for precision medicine in CD patients. Replicating of these findings in other cohorts is essential.

Guidelines for Diagnosis and Treatment of Chagas Disease

Chagas Disease: Epidemiology, Diagnosis, and Treatment

Tackling the Challenges of human Chagas Disease: a Comprehensive Review of Treatment Strategies in the Chronic Phase and Emerging Therapeutic Approaches

Unraveling the Missing Pieces: Exploring the Gaps in Understanding Chagas Cardiomyopathy

Alternative Approaches for the Treatment of Chagas Disease

Challenges in Chagas Disease Drug Development

The End Justifies the Means: Chagas Disease from a Perspective of the Host–Trypanosoma cruzi Interaction

Chagas disease in immunocompromised patients

Chagas Cardiomyopathy: From Romaña Sign to Heart Failure and Sudden Cardiac Death

Treatment options for Chagas Disease: a systematic review and meta-analysis applied to the preclinical studies using animal models

Chagas cardiomyopathy in Boston, Massachusetts: Identifying disease and improving management after community and hospital-based screening

What are the translational challenges associated with Chagas disease drug discovery?

Chronic Chagas Disease—the Potential Role of Reinfections in Cardiomyopathy Pathogenesis

Influence of angiotensin II type 1 receptors and angiotensin-converting enzyme I/D gene polymorphisms on the progression of Chagas' heart disease in a Brazilian cohort: Impact of therapy on clinical outcomes

Treatments and the Perspectives of Developing a Vaccine for Chagas Disease

Cardiac magnetic resonance imaging in Chagas’ disease: a parallel with electrophysiologic studies

Trypanosoma Cruzi Infection Induces a Global Host Cell Response in Cardiomyocytes

Chagas Disease in the Non-Endemic Area of Rome, Italy: Ten Years of Experience and a Brief Overview

Chagas Disease across the Ages: A Historical View and Commentary on Navigating Future Challenges

Preventing the Transmission of American Trypanosomiasis and Its Spread into Non-Endemic Countries

Analysis of dysautonomia in patients with Chagas Cardiomyopathy